Wuhan Keqian Biology Co Ltd Market Cap ($793.95 Million)
Market Cap & Net Worth: Wuhan Keqian Biology Co Ltd (688526)
Wuhan Keqian Biology Co Ltd market cap. Wuhan Keqian Biology Co Ltd (SHG:688526) has a market capitalization of $793.95 Million (CN¥5.43 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #9593 globally and #2426 in its home market, demonstrating a 3.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wuhan Keqian Biology Co Ltd's stock price CN¥11.64 by its total outstanding shares 466128056 (466.13 Million). Also see 688526 cash flow conversion for how efficiently the company converts equity into cash flow.
Wuhan Keqian Biology Co Ltd Market Cap History (2020–2026)
Wuhan Keqian Biology Co Ltd market cap history from 2020 to 2026. Data shows change from $2.71 Billion to $793.95 Million (-14.37% CAGR). Check current stock price of Wuhan Keqian Biology Co Ltd for real-time trading data and today's change.
Wuhan Keqian Biology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wuhan Keqian Biology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 688526 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.03x
Wuhan Keqian Biology Co Ltd's market cap is 1.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.55x
Wuhan Keqian Biology Co Ltd's market cap is 2.55 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.71 Billion | $843.23 Million | $447.80 Million | 3.21x | 6.04x |
| 2021 | $1.80 Billion | $1.10 Billion | $570.74 Million | 1.64x | 3.16x |
| 2022 | $1.48 Billion | $1.00 Billion | $409.52 Million | 1.48x | 3.62x |
| 2023 | $1.36 Billion | $1.06 Billion | $395.93 Million | 1.28x | 3.43x |
| 2024 | $974.71 Million | $941.92 Million | $382.35 Million | 1.03x | 2.55x |
Competitor Companies of 688526 by Market Capitalization
Companies near Wuhan Keqian Biology Co Ltd in the global market cap rankings as of November 8, 2026. Also see Wuhan Keqian Biology Co Ltd (688526) total assets for a full breakdown of the balance sheet.
Key companies related to Wuhan Keqian Biology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Wuhan Keqian Biology Co Ltd (2020–2026)
Market capitalization of Wuhan Keqian Biology Co Ltd from 2020 to today. Between 2020 and today, Wuhan Keqian Biology Co Ltd's market cap moved from $2.71 Billion to $ 793.95 Million, with a yearly change of -14.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥793.95 Million | -23.72% |
| 2025 | CN¥1.04 Billion | +6.79% |
| 2024 | CN¥974.71 Million | -28.29% |
| 2023 | CN¥1.36 Billion | -8.25% |
| 2022 | CN¥1.48 Billion | -17.92% |
| 2021 | CN¥1.80 Billion | -33.30% |
| 2020 | CN¥2.71 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Wuhan Keqian Biology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $793.95 Million USD |
| MoneyControl | $793.95 Million USD |
| MarketWatch | $793.95 Million USD |
| marketcap.company | $793.95 Million USD |
| Reuters | $793.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Wuhan Keqian Biology Co Ltd
Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. The company offers vaccines for pigs, poultry, and pets, as well as diagnostic reagents. Wuhan Keqian Biology Co.,Ltd was founded in 2001 and is based in Wuhan, China.